Category: Medical news

Affecting approximately 1 in 500 people, hypertrophic cardiomyopathy (HCM) is a genetic heart condition that causes the heart muscle to thicken. Mavacamten (brand name Camzyos) is the new drug for hypertrophic cardiomyopathy, specifically for the obstructive type (oHCM).

In early 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine), the first new oral non-opioid pain medication in over two decades. What is the name of the new non-opioid pain reliever causing a buzz in the medical community for its non-addictive properties and novel mechanism of action? It is Journavx, developed by Vertex Pharmaceuticals.